Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Lumakras and Sotorasib isomer. Its PubChem CID is 137278711.
Sotorasib
| CAS No | 2252403-56-6 |
|---|---|
| Molecular Formula | C30H30F2N6O3 |
| Molecular Weight | 560.6 g/mol |
| Synonyms | 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-yl-3-pyridinyl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer.
The listed CAS number is 2252403-56-6.
The listed molecular formula is C30H30F2N6O3.
The listed molecular weight is 560.6 g/mol.
6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-yl-3-pyridinyl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one.
The source lists Lumakras and Sotorasib isomer.